Cernostics Raises $2.5 Million in Series A1 Financing, Led by Illumina Ventures

TissueCypher® Barrett's Esophagus Assay is First Precision Medicine Platform for Prevention of Esophageal Cancer PITTSBURGH, March 21, 2018 -- (Healthcare Sales & Marketing Network) -- Cernostics, a privately-held company focused on delivering next... Diagnostics, Oncology, Venture Capital Cernostics, TissueCypher, Barrett's Esophagus, esophageal cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news